8-K: CVS Health Reports Mixed Q4 and Full-Year 2024 Results; Issues 2025 Guidance

CVS Health's Q4 results show revenue growth but a decline in earnings, with full-year results reflecting similar trends and the company issuing its 2025 financial guidance.

Summary

• CVS Health Corporation announced its Q4 and full-year 2024 operating results on February 12, 2025.
• Total revenues for Q4 2024 increased by 4.2% to $97.7 billion compared to the prior year.
• GAAP diluted EPS for Q4 was $1.30, while Adjusted EPS was $1.19.
• Full-year 2024 total revenues also increased by 4.2% to $372.8 billion.
• Full-year GAAP diluted EPS was $3.66, and Adjusted EPS was $5.42.
• The company generated $9.1 billion in cash flow from operations for the full year.
• CVS Health issued its full-year 2025 guidance, projecting a GAAP diluted EPS range of $4.58 to $4.83 and an Adjusted EPS range of $5.75 to $6.00.
• The company expects approximately $6.5 billion in cash flow from operations in 2025.
• The Health Care Benefits segment experienced an adjusted operating loss of $439 million in Q4 2024, compared to a $676 million profit in the prior year.
• The Health Services segment saw revenues decrease by 4.3% in Q4 2024.
• The Pharmacy & Consumer Wellness segment's revenues increased by 7.5% in Q4 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While revenue increased, earnings decreased, and the company faces challenges in its Health Care Benefits segment. The 2025 guidance provides some optimism, but overall, the results are mixed.

Positives

• Total revenues increased by 4.2% for both Q4 and the full year 2024.
• The Pharmacy & Consumer Wellness segment saw a 7.5% increase in revenues for Q4 2024.
• Prescriptions filled increased by 3.3% in the Pharmacy & Consumer Wellness segment for Q4 2024.
• The company anticipates generating approximately $6.5 billion in cash flow from operations in 2025.
• Same store prescription volume increased 5.9% and 6.8% on a 30-day equivalent basis for the three months and year ended December 31, 2024, respectively, compared to the prior year.

Negatives

• GAAP diluted EPS decreased in Q4 2024 to $1.30 from $1.58 in the prior year.
• Adjusted EPS decreased in Q4 2024 to $1.19 from $2.12 in the prior year.
• The Health Care Benefits segment reported an adjusted operating loss of $439 million in Q4 2024.
• Operating income decreased 29.8% in the three months ended December 31, 2024 compared to the prior year.
• Pharmacy claims processed decreased 16.9% and 18.2% on a 30-day equivalent basis for the three months and year ended December 31, 2024, respectively, compared to the prior year reflecting the previously announced loss of a large client.
• Adjusted operating income decreased 13.3% for the three months ended December 31, 2024 compared to the prior year primarily driven by continued pharmacy reimbursement pressure and decreased front store volume, partially offset by improved drug purchasing.

Risks

• The Health Care Benefits segment is facing increased utilization and the unfavorable impact of Medicare Advantage star ratings.
• The Health Services segment is experiencing revenue declines due to the loss of a large client and pharmacy client price improvements.
• The Pharmacy & Consumer Wellness segment is facing continued pharmacy reimbursement pressure and decreased front store volume.
• Interest expense increased due to higher debt levels.

Future Outlook

CVS Health anticipates a GAAP diluted EPS range of $4.58 to $4.83 and an Adjusted EPS range of $5.75 to $6.00 for the full year 2025, with cash flow from operations expected to be approximately $6.5 billion.

Management Comments

• David Joyner, CVS Health President and CEO, stated that the integrated model allows the company to deliver a simpler, connected experience that saves time, money, and improves health.
• He noted growth in key areas like the Pharmacy and Consumer Wellness segment while addressing industry-wide challenges impacting the Health Care Benefits segment.
• Management believes the company will be positioned for strong performance in 2025.

Industry Context

The results reflect the ongoing trends in the healthcare industry, including increased utilization, reimbursement pressures, and the shift towards integrated healthcare models. CVS Health is navigating these challenges while focusing on growth in key segments and cost management.

Comparison to Industry Standards

• CVS Health's performance can be compared to other major players in the healthcare and pharmacy benefits management space, such as UnitedHealth Group, Cigna, and Walgreens Boots Alliance.
• UnitedHealth Group, for example, has also been focused on expanding its integrated healthcare offerings and managing medical costs.
• Walgreens has been focusing on its pharmacy and retail operations, similar to CVS Health's Pharmacy & Consumer Wellness segment.
• Cigna is a major competitor in the Health Care Benefits segment.
• Benchmarking against these companies would provide a more comprehensive view of CVS Health's relative performance.

Stakeholder Impact

• Shareholders may be concerned about the decrease in earnings and the challenges in the Health Care Benefits segment.
• Employees may be affected by the restructuring plan and store closures.
• Customers may experience changes in service offerings as the company focuses on its integrated model.
• Suppliers may see shifts in demand as the company optimizes its operations.

Next Steps

• The company will hold a conference call to discuss the results.
• Management will focus on addressing challenges in the Health Care Benefits segment and driving growth in other areas.
• The company plans to close additional retail stores in 2025 as part of its restructuring plan.

Key Dates

Keywords

CVS Health, Financial Results, Earnings, Revenue, EPS, Guidance, Health Care Benefits, Pharmacy, Consumer Wellness